Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Recent advances in our understanding of the role of cytokine networks in inflammatory processes have led to the development of novel biological agents for the treatment of chronic inflammatory diseases. At the present time, significant efforts are focused on characterizing the complex signal transdu...

Full description

Saved in:
Bibliographic Details
Published in:Current Opinion in Pharmacology 2002-06, Vol.2 (3), p.316-321
Main Authors: Roshak, Amy K, Callahan, James F, Blake, Simon M
Format: Article
Language:English
Subjects:
IL-1
Inflammation
NF-κB
osteoarthritis
rheumatoid arthritis
signal transduction
TNF-α
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in our understanding of the role of cytokine networks in inflammatory processes have led to the development of novel biological agents for the treatment of chronic inflammatory diseases. At the present time, significant efforts are focused on characterizing the complex signal transduction cascades that are activated by these cytokines and, in turn, regulate their expression. The transcription factor NF-κB is a pivotal regulator of the inducible expression of key proinflammatory mediators, and activated NF-κB has been observed in several debilitating inflammatory disorders, including rheumatoid arthritis and osteoarthritis. In light of its central role in inflammation, the identification of inhibitors of NF-κB should provide novel therapeutics for the treatment of chronic joint disease . The upregulation of NF-kB in debilitating inflammatory joint diseases has resulted in a search for the identification of novel inhibitors for therapeutic treatment.
ISSN:1471-4892
1471-4973
DOI:10.1016/S1471-4892(02)00165-0